CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 160 enrolled
Drug / intervention
Womed Leafdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04963179
NCT04963179N/AActive

PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.

Womed·interventional·Posted Jul 15, 2021·Updated Mar 27, 2025

In Brief

A clinical study evaluating Womed Leaf for Asherman Syndrome and Intrauterine Adhesion. Active but no longer recruiting, targeting 160 participants across 15 sites in 7 countries.

Detailed Summary

PREG2 is a randomized controlled trial that aims to evaluate efficacy in preventing intrauterine adhesion recurrence after hysteroscopic adhesiolysis of a novel intrauterine barrier film named Womed Leaf

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, China, Czechia, France, Italy, Spain, Switzerland
Collaborators--

Timeline

N/AActive
202220232024202520262027
First PostedJul 15, 2021
Enrollment StartNov 29, 2021
Primary CompletionNov 11, 2023
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.0 years ago

Interventions

Womed Leafdevice

Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter. Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated. It is degraded and discharged naturally through the cervix and vagina.